A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.
- Conditions
- Idiopathic Restless Legs Syndrome
- Interventions
- Registration Number
- NCT00390689
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The objective of double blind phase in this trial is to compare the efficacy and safety at the fixed dose of 0.25 mg,0.5 mg and 0.75 mg pramipexole in RLS. The objective of open label phase in this trial is to investigate the long term safety and efficacy of pramipexole in RLS.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 154
-
Male or female patients between 20 and 80 years
-
Patients with a diagnosis of restless legs syndrome (RLS) according to the following diagnosis criteria of National institute of health (NIH)/International restless legs syndrome study group (IRLSSG):
- An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs.
- The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
- The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
- The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night.
-
Patients with a total score larger than 15 on the IRLS at Visit 2
- Premenopausal women who meet any of the following 1) to 3) 1) Patients who are pregnant or possibly pregnant 2) Patients who are lactating 3) Patients who wish to become pregnant during the study period
- Patients who cannot take adequate contraceptive measures
- Patients with a history of akathisia induced by neuroleptics
- Patients with diabetes mellitus requiring insulin therapy
- Patients who are judged to have microcytic anaemia by the investigator or sub-investigator
- Patients with a history or signs of peripheral neuropathy, myelopathy, multiple sclerosis, Parkinson's disease or other neurological diseases that may result in the occurrence of secondary RLS in the physical function tests or neurological tests
- Patients with other sleep disorders such as abnormal behaviour during Rapid eye movement (REM) sleep, narcolepsy and sleep apnoea syndrome (patients with an apnoea-hypopnoea index (AHI) exceeding 15 determined by polysomnography at the relevant trial site or those with loud snoring at least 5 nights/week and an experience of respiratory arrest during sleep or excessive daytime sleepiness)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pramipexole 0.25 mg once daily Pramipexole 0.125 mg tablet Pramipexole 0.25 mg given once daily Pramipexole 0.5 mg once daily Pramipexole 0.5 mg tablet Pramipexole 0.5 mg given once daily Pramipexole 0.75 mg once daily Pramipexole 0.125 mg tablet Pramipexole 0.75 mg given once daily Pramipexole 0.75 mg once daily Pramipexole 0.5 mg tablet Pramipexole 0.75 mg given once daily
- Primary Outcome Measures
Name Time Method Change From Baseline in International Restless Legs Syndrome (IRLS) Total Score at 6 Weeks Week 6 - change from baseline The International Restless Legs Syndrome Study Group (IRLSSG) proposes classification of severity based on the total score on the IRLS (0-10, mild; 11-20, moderate; 21-30, severe; 31-40, very severe). A decrease in the score of the IRLS by 10 or more points corresponds to the improvement of severity by one rank and has clinical importance. Therefore, the primary endpoint in the double-blind period was set as a decrease by 10 or more points in the mean change on the total score of the IRLS from the baseline to Visit 5 (last observation day in the double-blind period) at all doses of 0.25 mg, 0.5 mg, and 0.75 mg/day of pramipexole.
- Secondary Outcome Measures
Name Time Method IRLS Responder baseline to week 6 The percentage of patients with 50 % or more reduction of IRLS (The measure means the percentage of high responder on the trial medications)
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Score at 6 Weeks Week 6 - change from baseline PSQI developed to evaluate the quality of sleep is a self-recording questionnaire consisting of 18 questions focused on 7 factors such as sleep quality, sleep period time, sleep latency, sleep efficiency, sleep difficulty, use of hypnotics, and hindrance to activities of daily living due to daytime sleepiness. Each score (0-3 points) in the respective factors was added to calculate the total score (0-21 points). Rating scale scored from 0 (best sleep) to 21 (worst sleep).
Clinically Significant Abnormalities in Vital Signs (Blood Pressure and Pulse Rate in Both Supine and Standing Positions), ECG, Laboratory Tests - Double Blind Period. baseline to 6 weeks Change From Baseline in Japanese Version of the Epworth Sleepiness Scale (JESS) Total Score at 6 Weeks Week 6 - change from baseline ESS is a self-recording scale used to evaluate sleepiness experienced in daily activities and it consists of 8 items focused on specific situations such as reading books and watching television. Each score (0-3 points) to 8 questions was added simply to calculate the total ESS score. A Japanese translation of the ESS (a provisional version provided by the Japanese Respiratory Society) used so far had not been prepared through the international scale development and validation process, but the version prepared through this process was published at the 31st meeting of the Japanese Society of Sleep Research. The questions in JESS had been discussed with the original author of the ESS and their measurement concepts had been confirmed. The JESS is the Japanese version of ESS prepared through the international scale development and validation process. Rating scale scored from 0 (no daytime sleep) to 24 (worst daytime sleep)
Clinical Global Impression Global Improvement (CGI-I) Responder baseline to week 6 CGI is extensively used for risk-benefit evaluation (efficacy) of drug therapies. The CGI evaluates the severity and improvement in 7 ranks. It also evaluates the therapeutic effect and side effects in 4 ranks, separately. Rating scale from 1 (very much improved) to 7 (very much worse). The percentage of patients who were evaluated as 1(very much improved) or 2(much improved) by the investigator were considered responders.
Patient Global Impression (PGI) Responder baseline to week 6 PGI is used to evaluate a global impression by patients themselves in 7 ranks. Rating scale from 1 (very much better) to 7 (very much worse). The percentage of patients where the patient evaluated himself/herself as 1(very much better) or 2(much better)were considered responders.
Change From Baseline in International Restless Legs Syndrome (IRLS) Total Score at 52 Weeks for Open-Label Period Week 52 - change from baseline The International Restless Legs Syndrome Study Group (IRLSSG) proposes classification of severity based on the total score on the IRLS (0-10, mild; 11-20, moderate; 21-30, severe; 31-40, very severe).
IRLS Responder for Open-label Period baseline to week 52 The percentage of patients with 50 % or more reduction of IRLS (The measure means the percentage of high responder on the trial medications)
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Score at 52 Weeks for Open-Label Period Week 52 - change from baseline PSQI developed to evaluate the quality of sleep is a self-recording questionnaire consisting of 18 questions focused on 7 factors such as sleep quality, sleep period time, sleep latency, sleep efficiency, sleep difficulty, use of hypnotics, and hindrance to activities of daily living due to daytime sleepiness. Each score (0-3 points) in the respective factors was added to calculate the total score (0-21 points). Rating scale scored from 0 (best sleep) to 21 (worst sleep).
Change From Baseline in Japanese Version of the Epworth Sleepiness Scale (JESS) Total Score at 52 Weeks for Open-Label Period Week 52 - change from baseline ESS is a self-recording scale used to evaluate sleepiness experienced in daily activities and it consists of 8 items focused on specific situations such as reading books and watching television. Each score (0-3 points) to 8 questions was added simply to calculate the total ESS score. A Japanese translation of the ESS (a provisional version provided by the Japanese Respiratory Society) used so far had not been prepared through the international scale development and validation process, but the version prepared through this process was published at the 31st meeting of the Japanese Society of Sleep Research. The questions in JESS had been discussed with the original author of the ESS and their measurement concepts had been confirmed. The JESS is the Japanese version of ESS prepared through the international scale development and validation process. Rating scale scored from 0 (no daytime sleep) to 24 (worst daytime sleep)
Patient Global Impression (PGI) Responder at 52 Weeks for Open-Label Period baseline to week 52 PGI is used to evaluate a global impression by patients themselves in 7 ranks. Rating scale from 1 (very much better) to 7 (very much worse). The percentage of patients where the patient evaluated himself/herself as 1(very much better) or 2(much better)were considered responders.
Clinical Global Impression Global Improvement (CGI-I) Responder at 52 Weeks for Open-label Period baseline to week 52 CGI is extensively used for risk-benefit evaluation (efficacy) of drug therapies. The CGI evaluates the severity and improvement in 7 ranks. It also evaluates the therapeutic effect and side effects in 4 ranks, separately. Rating scale from 1 (very much improved) to 7 (very much worse). The percentage of patients who were evaluated as 1(very much improved) or 2(much improved) by the investigator were considered responders.
Possible Augmentation in RLS Symptoms at 52 Weeks for Open-Label Period baseline to week 52 Possible augmentation defined as persistence of a state in which RLS symptoms begin to occur 2 hours earlier than the usual time zone for 5 days or more a week
Trial Locations
- Locations (34)
248.627.031 Boehringer Ingelheim Investigational Site
🇯🇵Urasoe, Okinawa, Japan
248.627.037 Boehringer Ingelheim Investigational Site
🇯🇵Aichi-gun, Aichi, Japan
248.627.023 Boehringer Ingelheim Investigational Site
🇯🇵Kitakyusyu, Fukuoka, Japan
248.627.030 Boehringer Ingelheim Investigational Site
🇯🇵Kagoshima, Kagoshima, Japan
248.627.027 Boehringer Ingelheim Investigational Site
🇯🇵Kawasaki, Kanagawa, Japan
248.627.029 Boehringer Ingelheim Investigational Site
🇯🇵Fukuoka, Fukuoka, Japan
248.627.014 Boehringer Ingelheim Investigational Site
🇯🇵Fujisawa, Kanagawa, Japan
248.627.033 Boehringer Ingelheim Investigational Site
🇯🇵Kanazawa, Ishikawa, Japan
248.627.013 Boehringer Ingelheim Investigational Site
🇯🇵Kanagawa, Yokohama, Japan
248.627.024 Boehringer Ingelheim Investigational Site
🇯🇵Kitakyusyu, Fukuoka, Japan
248.627.025 Boehringer Ingelheim Investigational Site
🇯🇵Mitaka-shi, Tokyo, Japan
248.627.038 Boehringer Ingelheim Investigational Site
🇯🇵Koriyama, Fukushima, Japan
248.627.041 Boehringer Ingelheim Investigational Site
🇯🇵Koriyama, Fukushima, Japan
248.627.039 Boehringer Ingelheim Investigational Site
🇯🇵Kumamoto, Kumamoto, Japan
248.627.011 Boehringer Ingelheim Investigational Site
🇯🇵Otaru, Hokkaido, Japan
248.627.002 Boehringer Ingelheim Investigational Site
🇯🇵Sakai,Osaka, Japan
248.627.003 Boehringer Ingelheim Investigational Site
🇯🇵Kurume, Fukuoka, Japan
248.627.001 Boehringer Ingelheim Investigational Site
🇯🇵Shibuya-ku, Tokyo, Japan
248.627.004 Boehringer Ingelheim Investigational Site
🇯🇵Shimotsuga-gun,Tochigi, Japan
248.627.012 Boehringer Ingelheim Investigational Site
🇯🇵Sendai, Miyagi, Japan
248.627.010 Boehringer Ingelheim Investigational Site
🇯🇵Sapporo, Hokkaido, Japan
248.627.035 Boehringer Ingelheim Investigational Site
🇯🇵Sapporo, Hokkaido, Japan
248.627.040 Boehringer Ingelheim Investigational Site
🇯🇵Shinjuku-ku, Tokyo, Japan
248.627.016 Boehringer Ingelheim Investigational Site
🇯🇵Toyohashi, Aichi, Japan
248.627.018 Boehringer Ingelheim Investigational Site
🇯🇵Takatsuki,Osaka, Japan
248.627.019 Boehringer Ingelheim Investigational Site
🇯🇵Tokushima, Tokushima, Japan
248.627.032 Boehringer Ingelheim Investigational Site
🇯🇵Hiroshima, Hiroshima, Japan
248.627.022 Boehringer Ingelheim Investigational Site
🇯🇵Kochi, Kochi, Japan
248.627.034 Boehringer Ingelheim Investigational Site
🇯🇵Kodaira, Tokyo, Japan
248.627.015 Boehringer Ingelheim Investigational Site
🇯🇵Nagoya, Aichi, Japan
248.627.017 Boehringer Ingelheim Investigational Site
🇯🇵Osaka, Osaka, Japan
248.627.026 Boehringer Ingelheim Investigational Site
🇯🇵Otsu, Shiga, Japan
248.627.028 Boehringer Ingelheim Investigational Site
🇯🇵Tokorozawa, Saitama, Japan
248.627.036 Boehringer Ingelheim Investigational Site
🇯🇵Minato-ku, Tokyo, Japan